The experimental Alzheimer’s drug gantenerumab is the "first and only" anti-amyloid antibody being investigated for subcutaneous administration and could potentially be given to patients in the home, the drugmaker says.
Roche says updated data shows Tecentriq cocktail gives longer liver cancer survival
FILE PHOTO: A sign at a diagnostics site for Swiss pharmaceutical giant Roche is seen as the company said problems at a new warehouse delayed the dispatch of some products
ZURICH (Reuters) – Drugmaker Roche will present updated data confirming its immunotherapy Tecentriq, used in combination with Avastin, substantially improves overall survival in people with the most common form of liver cancer, the Swiss company said on Tuesday.
Follow-up data from a phase III trial taken at a median follow-up of 15.6 months showed that Tecentriq in combination with Avastin reduced the risk of death by 34%, the company said.